These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 28376458)

  • 21. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
    Shiffman D; Slawsky K; Fusfeld L; Devlin JJ; Goss TF
    Clin Ther; 2012 Jun; 34(6):1387-94. PubMed ID: 22560621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of population-based screening for diabetes and hypertension in India: an economic modelling study.
    Kaur G; Chauhan AS; Prinja S; Teerawattananon Y; Muniyandi M; Rastogi A; Jyani G; Nagarajan K; Lakshmi P; Gupta A; Selvam JM; Bhansali A; Jain S
    Lancet Public Health; 2022 Jan; 7(1):e65-e73. PubMed ID: 34774219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF; Heeg BM; Herlitz J; van Hout BA
    Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
    Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of population-based vascular disease screening and intervention in men from the Viborg Vascular (VIVA) trial.
    Søgaard R; Lindholt JS
    Br J Surg; 2018 Sep; 105(10):1283-1293. PubMed ID: 29691840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Priorities among effective clinical preventive services: results of a systematic review and analysis.
    Maciosek MV; Coffield AB; Edwards NM; Flottemesch TJ; Goodman MJ; Solberg LI
    Am J Prev Med; 2006 Jul; 31(1):52-61. PubMed ID: 16777543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.
    Gaziano TA; Opie LH; Weinstein MC
    Lancet; 2006 Aug; 368(9536):679-86. PubMed ID: 16920473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repeated tobacco-use screening and intervention in clinical practice: health impact and cost effectiveness.
    Solberg LI; Maciosek MV; Edwards NM; Khanchandani HS; Goodman MJ
    Am J Prev Med; 2006 Jul; 31(1):62-71. PubMed ID: 16777544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
    Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM;
    Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy.
    Ess SM; Szucs TD
    Ital Heart J; 2001 Mar; 2(3):181-8. PubMed ID: 11305529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of the 2014 U.S. Preventive Services Task Force (USPSTF) Recommendations for Intensive Behavioral Counseling Interventions for Adults With Cardiovascular Risk Factors.
    Lin J; Zhuo X; Bardenheier B; Rolka DB; Gregg WE; Hong Y; Wang G; Albright A; Zhang P
    Diabetes Care; 2017 May; 40(5):640-646. PubMed ID: 28213373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.
    Maciosek MV; Solberg LI; Coffield AB; Edwards NM; Goodman MJ
    Am J Prev Med; 2006 Jul; 31(1):72-9. PubMed ID: 16777545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective cost-effectiveness analysis of screening mammography.
    Stout NK; Rosenberg MA; Trentham-Dietz A; Smith MA; Robinson SM; Fryback DG
    J Natl Cancer Inst; 2006 Jun; 98(11):774-82. PubMed ID: 16757702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrated screening and treatment services for HIV, hypertension and diabetes in Kenya: assessing the epidemiological impact and cost-effectiveness from a national and regional perspective.
    Kasaie P; Weir B; Schnure M; Dun C; Pennington J; Teng Y; Wamai R; Mutai K; Dowdy D; Beyrer C
    J Int AIDS Soc; 2020 Jun; 23 Suppl 1(Suppl 1):e25499. PubMed ID: 32562353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
    Hay JW; Sterling KL
    Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.